Phase I study of NBTXR3 activated by radiotherapy in cisplatin-ineligible HNSCC patients

Journal of Clinical Oncology, 2021 · Le Tourneau C, Calugaru V, Takacsi-Nagy Z, Liem X, Papai Z, Fijuth J, et al.

Authors

Christophe Le Tourneau, Valentin Calugaru, Zoltan Takacsi-Nagy, Xavier Liem, Zsuzsanna Papai, Jacek Fijuth, Victor Moreno, Jordi Giralt, Sébastien Salas, Gilles Poissonnet, Emiliano Calvo, Bernard Doger, Olivier Choussy, Xavier Mirabel, Samar Krhili, Katell Bernois, Nicolas Fakhry, Stéphanie Wong-Hee-Kam, Edith Borcoman, Caroline Hoffmann

Institut Curie, Saint-Cloud, France; Institut Curie, Paris, France; Center of Radiotherapy-National Institute of Oncology, Budapest, Hungary; Centre Oscar Lambret, Lille, France; State Health Center, Hungarian Defense Forces, Oncology Department, Budapest, Hungary; Provita Prolife, Tomaszów Mazowiecki, Poland; START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain; Vall d’Hebron University Hospital, Barcelona, Spain; CEPCM Assistance Publique des Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France; Antoine-Lacassagne Anticancer center, Nice, France; START Madrid-CIOCC, Madrid, Spain; Hospital Universitario Fundacion Jimenez Diaz – START Madrid, Madrid, Spain; Oncology, Oscar Lambret Center, Lille, France; Nanobiotix, Paris, France; Hôpital Timone, AP-HM, Marseille, France; INSERM Unit U932 Immunity and Cancer, Institut Curie, Paris, France

Summary

Background: The non-surgical standard of care (SOC) for the treatment of locally advanced head and neck squamous cell carcinoma (LA HNSCC) patients is concurrent chemoradiation with high dose cisplatin or cetuximab in case of contra-indication to cisplatin. However elderly patients, and those with poor performance status, comorbidities, and/or intolerance, may not benefit from these SOC treatments and represent a high unmet need. New approaches are thus needed to improve clinical outcomes without adding toxicity. NBTXR3, a novel radioenhancer, composed of functionalized hafnium oxide nanoparticles, is injected once intratumorally and activated by radiotherapy (RT).NBTXR3 increases the RT energy deposit inside tumor cells and subsequently increases tumor cell death compared to RT alone, while sparing healthy tissues. We present here the results of the dose expansion part of the phase I study evaluating NBTXR3 plus intensity modulated radiation therapy (IMRT) in this population.

Methods: Patients with stage III-IVA or T3/T4 (AJCC/UICC TNM staging system 8th ed.) HNSCC of the oropharynx or oral cavity, ineligible to cisplatin or cetuximab and amenable for RT, received a single intratumoral injection of NBTXR3 and IMRT (70 Gy in 35 fractions /7 weeks). A classical 3 + 3 dose escalation design has tested four doses of NBTXR3, equivalent to 5, 10, 15, and 22% of baseline theoretical tumor volume. The RP2D established as 22% of baseline tumor volume is further tested in the dose expansion part. The primary endpoints of the dose expansion part are objective response rate (ORR) and complete response rate (CRR) of the primary tumor, by imaging according to RECIST 1.1. Safety is also evaluated.

Results: As of August 13, 2020, 43 patients have been treated in the phase I dose expansion part. The median age was 70.7 years old (range: 50.7- 89.9), 70% of patients had cardiac disorder risk, 44% had gastrointestinal disorder risk and 44% metabolic and nutrition disorder risk. The median tumor volume was 42.8 mL (range: 1.3 – 222.3). At a median time of 7.8 months after NBTXR3 injection, the ORR of the primary lesion was 83.9% and the CRR 67.7% in the evaluable population for efficacy (N = 31). Three patients (7%) experienced at least one serious adverse event (AE) related to the injection procedure and/or NBTXR3 which represented less than 1% of all reported AEs. RT-related toxicity was as expected with IMRT. Three deaths due to AEs related to RT and other causes were reported. The recruitment is ongoing and updated efficacy and safety results will be presented.

Conclusions: NBTXR3 intratumoral administration followed by IMRT may represent an option in elderly patients or patients with multiple comorbidities with LA-HNSCC who have limited therapeutic options. NBTXR3 activated by RT showed promising anti-tumor efficacy, supporting further evaluation in a phase III randomized trial. Clinical trial information: NCT01946867.

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.

CloseFermer